Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19
Jovan Milosavljevic, Navya Reddy Perkit, Sakshi Jhawar, Melbin Thomas, Justin Ling, Samuel Amankwah, Asha Mary Thomas
Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Objectives: To identify risk factors for severe disease and death among patients with diabetes and coronavirus disease 2019 (COVID-19) infection. Methods: This retrospective cohort study conducted at three hospitals included 733 consecutive patients with DM admitted with confirmed COVID-19 (March 1 -December 31, 2020). Multivariable logistic regression was performed to identify predictors of severe disease and death. Results: The mean age was 67.4 ± 14.3 years, 46.9% were males and 61.5% were African American. Among all patients, 116 (15.8%) died in the hospital. A total of 317 (43.2%) patients developed severe disease, 183 (25%) were admitted to an ICU and 118 (16.1%) required invasive mechanical ventilation. Increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history of chronic lung disease (OR, 1.49; 95% CI, 1.05e2.10) and increasing time since the last HbA1c test (OR, 1.25; 95% CI, 1.05e1.49) were the preadmission factors associated with increased odds of severe disease. Preadmission use of metformin (OR, 0.67; 95% CI, 0.47e0.95) or GLP-1 agonists (OR, 0.49; 95% CI, 0.27e0.87) was associated with decreased odds of severe disease. Increasing age (OR, 1.21; 95% CI, 1.09e1.34), co-existing chronic kidney disease greater than stage 3 (OR, 3.38; 95% CI, 1.67e6.84), ICU admission (OR, 2.93; 95% CI, 1.28e6.69) and use of invasive mechanical ventilation (OR, 8.67, 95% CI, 3.88e19.39) were independently associated with greater odds of in-hospital death. Conclusion: Several clinical characteristics were identified to be predictive of severe disease and in-hospital death among patients with underlying diabetes hospitalized with COVID-19.
Author contributions J.M.: data collection, data analysis, writing e original draft; N.P.: data collection, writing e original draft; M.T., S.J., J.L. and S.A.: data collection, writing e review & editing; A.T.: conceptualization, supervision, writing -review & editing. All authors read and approved the final manuscript.
Conflict of interest The authors declare that they have no competing or conflicts of interests.
References
Agarwal, Schechter, Southern, Crandall, Tomer, Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019, Diabetes Care,
doi:10.2337/dc20-1543Aleem, Samad, Slenker, Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
Apicella, Campopiano, Mantuano, Mazoni, Coppelli et al., COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30238-2Bai, Lian, Li, Zhang, Qiao, The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice, Microb Pathog,
doi:10.1016/j.micpath.2020.104645Bello-Chavolla, Bahena, Opez, Ne, Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico, J Clin Endocrinol Metab,
doi:10.1210/clinem/dgaa346Bode, Garrett, Messler, Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States, J Diabetes Sci Technol,
doi:10.1177/1932296820924469Buuren S Van, Groothuis-Oudshoorn, Mice: multivariate imputation by chained equations in R, J Stat Software,
doi:10.18637/jss.v045.i03Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia,
doi:10.1007/s00125-020-05180-xHariyanto, Intan, Hananto, Putri, Kurniawan, Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and metaregression, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2021.109031Izcovich, Ragusa, Tortosa, Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review, PLoS One,
doi:10.1371/journal.pone.0241955Klonoff, Messler, Umpierrez, Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis, Diabetes Care,
doi:10.2337/dc20-1857Mehta, Kohn, Koliwad, Rushakoff, Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes, BMJ Open Diabetes Res Care,
doi:10.1136/bmjdrc-2021-002203Mesas, Cavero-Redondo, Alvarez-Bueno, Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions, PLoS One,
doi:10.1371/journal.pone.0241742Rosenthal, Cao, Gundrum, Sianis, Safo, Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.29058Wood, White, Royston, How should variable selection be performed with multiply imputed data?, Stat Med,
doi:10.1002/sim.3177Xian, Liu, Nilsson, Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation, Immunity,
doi:10.1016/j.immuni.2021.05.004Yan, Yang, Wang, Clinical characteristics and outcomes of patients with severe covid-19 with diabetes, BMJ Open Diabetes Research and Care,
doi:10.1136/bmjdrc-2020-001343Yang, Sun, Zhang, Zhang, The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2021.108977Zhu, She, Cheng, Association of blood glucose control and outcomes in patients with COVID-19 and preexisting type 2 diabetes, Cell Metabol,
doi:10.1016/j.cmet.2020.04.021
